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Abstract
Background: Diagnostic accuracy of lymphoma, a heterogeneous cancer, is essential for patient management.
Several ancillary tests including immunophenotyping, and sometimes cytogenetics and PCR are required to aid
histological diagnosis. In this proof of principle study, gene expression microarray was evaluated as a single
platform test in the differential diagnosis of common lymphoma subtypes and reactive lymphadenopathy (RL) in
lymph node biopsies.
Methods: 116 lymph node biopsies diagnosed as RL, classical Hodgkin lymphoma (cHL), diffuse large B cell
lymphoma (DLBCL) or follicular lymphoma (FL) were assayed by mRNA microarray. Three supervised classification
strategies (global multi-class, local binary-class and global binary-class classifications) using diagonal linear
discriminant analysis was performed on training sets of array data and the classification error rates calculated by
leave one out cross-validation. The independent error rate was then evaluated by testing the identified gene
classifiers on an independent (test) set of array data.
Results: The binary classifications provided prediction accuracies, between a subtype of interest and the remaining
samples, of 88.5%, 82.8%, 82.8% and 80.0% for FL, cHL, DLBCL, and RL respectively. Identified gene classifiers
include LIM domain only-2 (LMO2), Chemokine (C-C motif) ligand 22 (CCL22) and Cyclin-dependent kinase
inhibitor-3 (CDK3) specifically for FL, cHL and DLBCL subtypes respectively.
Conclusions: This study highlights the ability of gene expression profiling to distinguish lymphoma from reactive
conditions and classify the major subtypes of lymphoma in a diagnostic setting. A cost-effective single platform
“mini-chip” assay could, in principle, be developed to aid the quick diagnosis of lymph node biopsies with the
potential to incorporate other pathological entities into such an assay.
Background
The increasing complexity of lymphoma diagnosis and
classification is the result of a vastly improved under-
standing of its underlying molecular pathogenesis and
resultant attempts to group subtypes of lymphoma in a
clinically and biologically meaningful manner. From a
practical perspective, this increasing complexity places
great demands on the pathologist. Accurate diagnosis
and classification of lymphoma in lymph node biopsies
requires pathological evaluation utilising morphological
analysis of an acceptable biopsy specimen, together with
a series of supplementary tests including immunopheno-
typing by immunohistochemistry and flow cytometry,
and increasingly cytogenetics, FISH and PCR data [1].
Such ancillary tests can be costly and time consuming,
requiring specialised technicians and analytical experi-
ence from multiple divisions of a pathology laboratory.
Of benefit would be a cost-effective, single platform
ancillary test that provides a rapid standardised diagno-
sis of lymphoma and recognition of major subtypes,
allowing more selective use of other ancillary tests dur-
ing subsequent assessment by the pathologist.
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novel approach to disease classification based on the
molecular biology of the disease. This ‘genetic finger-
print’ data thus allows the identification and classifica-
tion of individual tissue samples according to their
distinct gene expression profiles. There is a significant
body of research employing GEP in lymphoma, having
been used for a number of purposes including distin-
guishing closely related lymphoma phenotypes such as
diffuse large B-Cell lymphoma (DLBCL) versus Burkitt
lymphoma [2] and DLBCL from primary mediastinal
B-cell lymphoma [3], to trace malignant lymphoma phe-
notypes to “normal cell of origin” [4] and to identify
expression profiles linked to tumour prognosis [5].
However, there is a lack of publications that address the
potential value of gene expression microarray in aiding
the routine diagnosis and classification of lymphoma in
tissue biopsies from individual cases suspected of lym-
phoma. The feasibility of GEP as a tool to classify
tumour tissue has been examined for other cancers,
such as breast [6], colon [7], prostate [8] and renal
tumours [9].
Distinct from previous microarray studies of lym-
phoma, this single institute study evaluated whether
gene expression microarray as a single platform could
be used to distinguish three major subtypes of lym-
phoma and non-malignant reactive lymphadenopathy
(RL) in individual lymph node samples. To our knowl-
edge, this study is a first attempt to apply such a strat-
egy to lymph node specimens across different subtype
diagnoses in a diagnostic setting. Our heterogeneous
study set enabled the identification of gene signatures
that are likely an accurate representation of each diag-
nostic type, given that this was determined by compar-
ing each diagnostic type against the remaining cases by
binary classification approach.
Methods
Patient samples
Lymph node specimens from patients undergoing biopsy
for suspected lymphoma were identified by the Depart-
ment of Pathology at St Vincent’s Hospital, Sydney. Sam-
ples were collected subject to written consent for this
human research ethics approved study (H00/028/1). A
portion of the fresh biopsy specimen (≥2m m
3)
was collected in RNAlater solution (Ambion, Foster City,
CA) and then cryopreserved in liquid nitrogen. A further
five biopsy samples (two cHL, two DLBCL, one FL) were
obtained from the Newcastle Mater Misericordiae Hospi-
tal. The diagnosis and classification of each specimen was
made or reviewed by an expert haematopathologist (JT)
practising at our centre [10], according to the WHO
Classification of Tumours of Haematopoietic and Lym-
phoid tissue 2001 [11]. All samples were collected during
2001-07 and analysed prior to the 2008 update of this
classification system. Most cases (n = 16) of DLBCL were
subclassified into germinal centre B (GCB) and non-GCB
cell types (n = 5 and n=11 respectively) by immunohisto-
chemistry according to the Hans algorithm [12]. The 23
cases of RL included reactive hyperplasia (n = 16), reac-
tive hyperplasia with progressive germinal centre trans-
formation (n = 3) or granuloma related to toxoplasmosis
(n = 1), dermatopathic lymphadenitis (n =1 )a n dn o r m a l
(n = 2).
RNA and Microarray assays
Frozen lymph node tissue was homogenised in TRIzol
reagent (Invitrogen, Victoria, Australia) using a pellet
pestle and total RNA isolated using RNeasy micro-
column purification (Qiagen, Doncaster, Australia). The
integrity of total RNA was assessed by denaturing agar-
ose gel electrophoresis (1% agarose, 221 mM formalde-
hyde, 20 mM MOPS, 5 mM sodium acetate, 1 mM
EDTA). Only samples with distinct 28 S and 18 S RNA
bands were assayed by microarray. The total RNA
extracted from granulocyte colony-stimulating factor
mobilised peripheral blood stem cells (PBSC) samples
from 10 healthy individuals (collected with informed
consent) were pooled and used as the reference RNA
for microarray assays. Two-colour fluorescent probe
synthesis was carried out on 2 μg of patient (Cy5 - Red)
and reference (Cy3 - Green) RNA and then competi-
t i v e l yh y b r i d i s e dt oam i c r o a r r a yu s i n gt h e3 D N A
900MPX kit (Genisphere, Hatfield, PA) according to the
manufacturer’s protocol. A GenePix 4000A scanner and
GenePix Pro 3.0 image analysis software (Molecular
devices, Sunnyvale, CA) was used to capture microarray
images and quantify fluorescent signals from each fea-
ture. The microarrays used in this study were printed by
the Adelaide Microarray Facility (Adelaide, Australia)
using the Compugen library of 19000 70-mer oligonu-
cleotides, which covers over 12000 generic human
genes.
Preprocessing of array data
Data from GenePix result files were pre-processed by
within-array print-tip Lowess normalisation. The quality
of each array was assessed prior to analysis to ensure
only arrays of sufficient quality were retained. A quality
score was obtained using the QC CV scoring from
arrayQuality [13]. The microarray data with clinical
information have been deposited in NCBI’sG e n e
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.
gov/geo/) and are accessible through GEO Series acces-
sion number GSE23647. This study is comprised
from two batches of arrays developed over two years.
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maintain the independence of the two datasets.
GEP classification analysis
The statistical analysis was performed using the R statis-
tical software version 2.8.1. Microarray gene expression
data from 81 patients of batch-1 arrays (training set)
were used to develop a diagnostic profile. An indepen-
dent series consisting of a further 35 patients (batch-2
arrays - test set) were used to independently assess the
classification accuracy of the profile. The patient infor-
mation, diagnosis and number of samples used in the
training and test dataset of this study are indicated in
Table 1.
The ability of GEP to ascertain the correct diagnosis
of each biopsy was assessed via diagonal linear discrimi-
nant analysis (DLDA) with classification error rates in
the training set determined by leave one out cross-vali-
dation (LOOCV). The ratio of between sum of squares
to within sum of squares (bss/wss) criteria was used for
feature selection performed within each CV fold. As a
measure of discriminative power in two-class classifica-
tion, the selective use of features ranked high in bss/wss
enriches for potential biomarkers of interest. The top
ranked bss/wss genes ranging from 10-500 (increments
of 10) were assessed within the classification develop-
ment to identify the number of genes required to obtain
a minimal (optimal) cross-validation error rate (see
Additional file 1). The classification power of the deter-
mined optimal set of genes was then tested on the inde-
pendent test set sample. Firstly, the results for each
classification built from training datasets are expressed
in terms of a classification accuracy rate (%), which
represents the similarity between the pathological clini-
cal diagnosis and the microarray diagnosis [14]. The
accuracy rate of training datasets was determined by
subtracting the LOOCV-error rate (%) from 100%.
A separate dataset was then used to obtain independent
error and accuracy rates. A DLDA classification rule
was constructed from the complete training set data
using the optimal number of genes estimated via the
LOOCV stage of the analysis. This classification rule
was then used to classify the independent data. The
independent test dataset accuracy rate denotes the per-
centage of samples in the test dataset that have been
correctly diagnosed using the molecular signatures iden-
tified from classification of the training dataset.
To examine the feasibility of GEP to classify RL versus
lymphoma and subtypes of lymphoma, the expression data
was analysed according to three different approaches:
1. A global (all data) multi-class strategy was per-
formed to classify the four main classes examined in
this study (RL, cHL, FL and DLBCL) in a single step.
2. A series of independent local (selected data) pair-
wise (binary-class) comparisons of the four main classes
examined was made. Comparisons included lymphoma
versus RL, cHL versus NHL (inclusive of 3 and 17 cases
respectively of rare T- and B cell lymphoma subtypes),
and lastly, FL versus DLBCL, the two most prevalent
forms of NHL in Caucasian populations [10]. These will
be refered to as the ‘local binary comparisons’
3. A number of ‘global binary comparisons’ were per-
formed by pair-wise comparisons of samples from an
individual subtype versus the remaining data.
For all classification strategies, both LOOCV and inde-
pendent test set accuracy rates were determined as men-
tioned above.
Heat maps
Heat maps of the set of genes (classifiers) yielding the
optimal LOOCV accuracy rates were produced. Cluster-
ing was performed for both samples and genes utilising
hierarchical clustering with Euclidean distance as the
dissimilarity function with complete linkage agglomera-
tion. Dendrograms are displayed on the appropriate axis
of the heat map.
Results
Microarray analysis of lymph node biopsies
Microarrays quantifying gene expression in lymph node
biopsies (n = 142) suspected of lymphoma were assessed
for quality using the arrayQuality package. Arrays with a
C VQ Cs c o r eo f> 1w e r ei d e n t i f i e da ss u b - o p t i m a li n
quality and subsequently removed from analysis to
Table 1 Summary of the biopsies in each disease
category examined by microarray
Training set
(n = 81)
Test set
(n = 35)
Total
(n = 116)
Patient characteristics
Male (%) 64% 54%
Age range 16-83 21-82
Median age 53 56
Diagnosis
RL 16 7 23
cHL 12 7 19
NHL 53 21 74
DLBCL 8 11 19
FL 25 10 35
Other NHL* 20 0 20
The table summarises the overall number of biopsies for each subtype
examined and also the corresponding numbers divided into training and test
sets for analysis.
*Includes cases of Burkitt-like lymphoma, MALT lymphoma, mantle cell
lymphoma, marginal zone lymphoma, small lymphocytic lymphoma/chronic
lymphocytic leukaemia, anaplastic large cell lymphoma, extranodal NK/T-cell
lymphoma, and other T-cell lymphomas.
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of the diagnosis of each of these biopsies and number of
each subtype examined is shown in Table 1.
A diagnostic profile for the global multi-class
approach consisting of 50 genes was developed, and
demonstrated an optimal LOOCV accuracy rate of
83.6% for the diagnosis of biopsies as RL, HL, FL or
DLBCL (Table 2). Most cases from the diagnostic
classes examined in this study clustered distinctly
together by hierarchical clustering, with the exception of
DLBCL (Figure 1A). An accuracy rate of only 68.6% was
achieved when the same profile of genes were tested on
an independent test set (Table 2).
Using local binary classification (lymphoma versus RL,
cHL versus NHL, and FL v DLBCL groups; Table 2)
LOOCV accuracy rates at each independent comparison
ranged from 84.8-89.2%. This high rate of accuracy was
reflected in hierarchical clustering analysis, which showed
only 5 samples (1 HL and 4 NHL) clustered incorrectly
in the NHL versus HL comparison (Figure 1B), and a
clear-cut separation between FL and DLBCL samples
achieved using only 10 unique classifying genes (Figure
1C). Independent test set accuracy rates for these com-
parisons were all greater than 76% (Table 2). See Addi-
tional files 2 and 3 for the lists of top 10 and 20 classifier
genes distinguishing HL from NHL and FL from DLBCL.
Given the higher independent test set accuracy rates
when only two defined types of diagnoses (classes) were
considered in each analysis, we next investigated if we
can diagnose a specific disease type compared to the
remainder of all case types examined in this study. The
gene classifiers, identified from this type of comparison
are likely more specific to the disease type itself, as
opposed to signature genes identified purely from a
comparison of two subtypes. Samples were classified by
comparing each subtype of lymphoma or RL to all
remaining cases at the global level and accuracy rates
for this type of binary classification determined. Based
on varying optimal number of genes, LOOCV accuracy
rates of training sets were all above 82%, with test set
accuracy rates of 88.5%, 82.8%, 82.8% and 80.0% for FL,
cHL, DLBCL and RL respectively.
Identified gene classifiers of RL, cHL, DLBCL and FL
Strong classifiers of reactive node tissue included the
lower expression of a cohort of immune-response
related genes compared to tissue diagnosed with lym-
phoma (Table 3). Reduced expression in reactive node
tissue was also observed for genes such as TATA box
binding protein (TBP)-associated factor 140 kDa (TAF3)
and Lim domain binding 2 (LDB2). Molecular classifiers
identified for cases of cHL include the expression of a
selection of chemokine ligands, and the transcription
factor STAT1 (Table 4). The gene LIM domain only-2
(LMO2) was highly differentially expressed in FL com-
pared to the remainder of cases examined (Table 5)
whilst high expression of cyclin-dependent kinase inhibi-
tor 3 (CDKN3) transcripts was associated with DLBCL
(Table 6). A total of 31 genes within any of the four
lists of genes identified from binary-class analyses are
common to the 38 annotatable genes (of 50 probes)
identified from our multi-class analysis. See Additional
file 4 for the complete list of classifiers (genes) for all
classifications. The clustering of these identified classi-
fiers is not influenced by clinical covariates such as the
age or gender (Additional file 5).
Discussion
In the present study, we used GEP microarrays to ana-
lyse 116 lymph node biopsies to assess the feasibility of
this technology as a diagnostic tool in a clinical setting.
This study is preceded by a significant body of research
on GEP of lymphoma that has focused on understand-
ing the pathogenesis of individual subtypes of lymphoma
and refining the diagnosis and prognosis of these sub-
types. However, our aim was to examine the practical
question of whether GEP could be used to classify
lymph node samples into the major subtypes of lym-
phoma and also to distinguish them from reactive
lymph nodes.
Table 2 The accuracy rates resulting from GEP classification of lymph node biopsies into selected subtypes
Comparison Subtypes Optimal number
of probes
Training set
accuracy rate (%)
Test set
accuracy rate* (%)
Global multi-class RL v cHL v FL v DLBCL 50 83.6 68.6
Local binary-class RL v Lymphoma 130 87.7 80.0
cHL v NHL 40 89.2 82.1
FL v DLBCL 10 84.8 76.1
Global binary-class cHL v remaining cases 30 91.4 82.8
FL v remaining cases 60 82.7 88.5
DLBCL v remaining cases 490 87.7 82.8
*The reported independent test set accuracy rates indicate the proportion of correctly classified cases from the total number assessed in the test datasets.
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Figure 1 Hierarchical clustering of lymph node samples comparing distinct subtypes of lymphoma. Heatmaps depict A. Multi-class
analysis for cases of RL (grey, n = 16), cHL (black, n = 12), DLBCL (yellow, n = 8) and FL (magenta, n = 25); B. cHL (grey, n = 12) versus NHL
(black, n = 53) and C. FL (grey, n = 25) versus DLBCL (black, n = 8). The columns represent the samples and rows represent the solicited genes.
Each cell within the grid is indicative of the gene expression level for an individual sample with colour used to depict intensity on a graduating
red (high) to green (low) scale. See Additional files 2 and 3 for the lists of top 10 and 20 classifier genes distinguishing HL from NHL and FL
from DLBCL.
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cHL, DLBCL and FL origin was examined with three
strategies: global multi-class classification; local binary-
class and global binary-class classification. The global
multi-class approach classified each sample into one of
the four diagnostic types with limited accuracy, which is
known to decrease when more than two classes are con-
sidered simultaneously in linear classification algorithms
[15]. Our binary comparisons, which compared a parti-
cular diagnostic type with either another type (local) or
Table 3 Top 20 annotated classifier genes of RL samples
Accession number Gene name Symbol Fold change
AF126749 ATXN8 opposite strand (non-protein coding) ATXN8OS 1.65
AL117661 TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kDa TAF3 0.71
NM_006107 LUC7-like 3 (S. cerevisiae) LUC7L3 0.68
AK025953 Myosin light chain kinase MYLK 0.55
NM_004367 Chemokine (C-C motif) receptor 6 CCR6 0.50
X64983 Olfactory receptor, family 10, subfamily D, member 3 pseudogene OR10D3P 0.48
AK024040 Hypothetical LOC148413 LOC148413 0.48
AF085877 Hypothetical protein LOC254100 LOC254100 0.47
NM_001290 LIM domain binding 2 LDB2 0.46
J02639 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 SERPINA5 0.43
NM_002989 Chemokine (C-C motif) ligand 21 CCL21 0.42
X87888 Immunoglobulin lambda locus IGL@ 0.37
AF026932 Immunoglobulin lambda locus IGL@ 0.37
AJ270695 Basic helix-loop-helix family, member e41 BHLHE41 0.32
X87890 Immunoglobulin lambda locus IGL@ 0.31
U50342 Immunoglobulin kappa constant IGKC 0.29
AF035799 Immunoglobulin kappa variable 3-20 IGKV3-20 0.28
AF035787 Immunoglobulin heavy variable 3-48 IGHV3-48 0.28
AF035035 Immunoglobulin kappa variable 1D-8 IGKV1D-8 0.27
X57772 Immunoglobulin lambda variable 6-57 IGLV6-57 0.25
Genes are ranked from high to low fold change (differential expression in reactive versus remainder of samples).
Table 4 The top 20 annotated classifier genes of cHL
Accession number Gene name Symbol Fold change
NM_006152 Lymphoid-restricted membrane protein LRMP 2.83
NM_005582 CD180 molecule CD180 1.65
NM_002382 MYC associated factor X MAX 0.65
NM_006564 Chemokine (C-X-C motif) receptor 6 CXCR6 0.57
NM_017458 Major vault protein MVP 0.55
NM_015364 Lymphocyte antigen 96 LY96 0.52
D17028 Prosaposin PSAP 0.51
NM_000167 Glycerol kinase GK 0.51
NM_018664 Basic leucine zipper transcription factor, ATF-like 3 BATF3 0.48
NM_006137 CD7 molecule CD7 0.45
NM_006018 G protein-coupled receptor 109B GPR109B 0.43
NM_000579 Chemokine (C-C motif) receptor 5 CCR5 0.40
NM_003329 Thioredoxin TXN 0.36
M36693 Superoxide dismutase 2, mitochondrial SOD2 0.34
NM_007315 Signal transducer and activator of transcription 1, 91 kDa STAT1 0.34
M26123 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 SERPINA1 0.33
NM_002258 Killer cell lectin-like receptor subfamily B, member 1 KLRB1 0.32
NM_002990 Chemokine (C-C motif) ligand 22 CCL22 0.29
NM_001276 Chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 0.24
NM_002987 Chemokine (C-C motif) ligand 17 CCL17 0.18
Genes are ranked from high to low fold change (differential expression in cHL versus remainder of samples).
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(>80%) accuracy rates for independent test sets, except
when comparing FL to DLBCL (76.1%), the subtype that
was most frequently misclassified. This limitation of
GEP in classifying DLBCL may be related to the high
degree of heterogeneity of the disease itself. Distinct
molecular forms of DLBCL have been identified in other
GEP studies [4,16,17], although this does not readily
explain the misclassified cases of this study, which
included both GCB and non-GCB DLBCL as judged by
Table 5 The top 20 annotated classifier genes of FL
Accession number Gene name Symbol Fold change
NM_004244 CD163 molecule CD163 3.20
X57772 Immunoglobulin lambda variable 6-57 IGLV6-57 3.03
NM_005502 ATP-binding cassette, sub-family A (ABC1), member 1 ABCA1 1.86
NM_005080 X-box binding protein 1 XBP1 1.86
NM_020397 Calcium/calmodulin-dependent protein kinase ID CAMK1D 1.83
NM_000153 Galactosylceramidase GALC 1.43
AF298812 Ectodysplasin A2 receptor EDA2R 0.72
NM_013340 Protocadherin beta 1 PCDHB1 0.72
AB046800 Leucine rich repeat containing 4C LRRC4C 0.70
NM_016524 Synaptotagmin XVII SYT17 0.70
NM_005582 CD180 molecule CD180 0.69
NM_014212 Homeobox C11 HOXC11 0.64
NM_014146 Linker for activation of T cells family, member 2 LAT2 0.63
AK001057 Hypothetical LOC114130 MGC16384 0.63
NM_006822 RAB40B, member RAS oncogene family RAB40B 0.59
NM_002753 Mitogen-activated protein kinase 10 MAPK10 0.55
NM_000319 Peroxisomal biogenesis factor 5 PEX5 0.49
AB033107 Zinc finger protein 608 ZNF608 0.46
NM_000869 5-hydroxytryptamine (serotonin) receptor 3A HTR3A 0.38
NM_005574 LIM domain only 2 (rhombotin-like 1) LMO2 0.37
Genes are ranked from high to low fold change (differential expression in FL versus remainder of samples).
Table 6 The top 20 annotated classifier genes of DLBCL
Accession number Gene name Symbol Fold change
NM_000439 Proprotein convertase subtilisin/kexin type 1 RBM16 2.03
AF111846 Transcribed locus CCNB1 1.54
NM_000492 Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) TFRC 0.66
NM_017421 Coenzyme Q3 homolog, methyltransferase (S. cerevisiae) SLC25A4 0.65
AL137452 Protein arginine methyltransferase 10 (putative) PGD 0.63
NM_016138 Coenzyme Q7 homolog, ubiquinone (yeast) CDKN3 0.63
NM_014726 TBK1 binding protein 1 CCT8 0.63
AL049705 Mitochondrial ribosomal protein S14 FKBP4 0.61
NM_018320 Ring finger protein 121 BZW2 0.61
NM_003566 Early endosome antigen 1 CCT3 0.60
NM_006231 Polymerase (DNA directed), epsilon GMPS 0.56
NM_015902 Ubiquitin protein ligase E3 component n-recognin 5 MSI1 0.56
NM_002626 Phosphofructokinase, liver MMRN1 0.55
NM_001634 Adenosylmethionine decarboxylase 1 SLMAP 0.55
NM_006476 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G NDUFV1 0.53
NM_007159 Sarcolemma associated protein SBNO1 0.53
NM_006330 Lysophospholipase I ESPL1 0.51
NM_003384 Vaccinia related kinase 1 MYO19 0.49
NM_006585 Chaperonin containing TCP1, subunit 8 (theta) CYC1 0.47
NM_001151 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 ANAPC5 0.47
Genes are ranked from high to low fold change (differential expression in DLBCL versus remainder of samples).
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partial involvement of a tissue biopsy by lymphoma can-
not be excluded, sampling error may also contribute to
classification error rates. In regards to the comparison
of RL with lymphoma, the two RL samples misclassified
were both reactive hyperplasia. It should be noted that
our reactive nodes were unselected and as such not all
of which would necessarily have been B-cell predomi-
nant reactions. Therefore the random sampling of reac-
tive nodes, which have different compartments, may
contribute to sampling error. The accuracy to distin-
guish benign from malignant may be improved by
increasing the number of cases used to build the classifi-
cation, especially since there is an imbalance in the
number of reactive biopsies (23) compared to the num-
ber of cancerous cases (93).
Application of our findings to clinical practice would
require a much larger scale study to not only verify our
identified genetic signature of particular types but also
to assess the profile of uncommon lymphoma subtypes.
We nonetheless feel that this work represents an impor-
tant step in testing the principle of using GEP, based on
simple and inexpensive arrays, as a diagnostic ancillary
test for lymph node biopsy. We found that our labora-
tory practices were easily adapted to allow routine allo-
cation of a portion of biopsy specimen for microarray as
routine tests such as flow cytometry and cytogenetics,
for diagnosis of lymphoma, also require fresh specimen
(not formalin fixed). The development of new techni-
ques such as quantitative nuclease protection assays on
formalin-fixed, paraffin-embedded tissue blocks would
overcome any difficulty in obtaining fresh tissue for
microarray gene expression profiling and make GEP
much more widely available even in small biopsies [18].
The 18% technical exclusion rate of samples arrayed
in this study hampers the diagnostic utility of microar-
ray. However, increased familiarity with the assay will
reduce the exclusion rate, and in laboratories with a lim-
ited caseload, referral to a centralised service may be
preferable. Given the substantial improvement of micro-
array technology since the initiation of this study, the
use of newer genome-wide microarray platforms such as
Illumina bead arrays would also improve the utility of
this technology and contribute to reducing the technical
exclusion rate seen in this study. Incorporation of
microRNA array data [19] may also be appropriate,
especially given the reported stability of microRNA
expression [20].
In our study, 13 of the 40 classifier genes identified
from a specific (local) comparison of cHL with NHL
were also strong classifiers when cHL was globally com-
pared to both NHL and reactive samples. This indicates
that our classification strategy encompasses unique gene
sets that can classify across more than two types of
pathological conditions. Although some gene classifiers
identified in our study were common to other reported
GEP studies, the absence of some previously identified
key classifiers may be due to variable probe make-up
across different microarray platforms or resulting from
differences in the type of diagnostic classes used in our
classification compared to most published GEP studies
[21]. Our distinct global binary comparisons would have
likely identified gene signatures that represent the parti-
cular diagnostic type in question as it was compared to
a mixture of lymphoma subtypes and non-cancerous
samples.
The fact that high expression of CD7, CCL17 and
STAT1 has been reported to be associated with cHL sup-
ports the reliability of our microarray data presented in
this study [22-24]. As Hodgkin and Reed-Sternberg cells
only account for on average 1% of the mixed cell types
present in HL infiltrates, it is likely that the expression of
some of the HL classifiers are derived from the stromal
cell population. This should not influence the applicabil-
ity of lymph node GEP to the diagnosis of HL given that
this stromal reaction is likely to be similar across differ-
ent HL samples and that their gene expression profiles
have been reported to predict the outcome of HL [25].
Similarly for FL, our detected reduced expression of
CD163, a macrophage marker, may reflect a low number
of macrophages present in the node microenvironment
in many cases of FL. The importance of this information
is not diminished as increased reactive macrophages in a
rare subset of FL have been reported to be associated
with poorer survival [26]. LMO2, another strong molecu-
lar classifier identified for FL, has been reported to be
expressed in approximately 50% of FL [27]. However, it is
better known as a key gene expressed in GCB cell type of
DLBCL [4] and as a strong predictor of superior outcome
in DLBCL [28]. Given the importance of LMO2 expres-
sion in DLBCL, its absence in our list of top 20 classifying
genes of DLBCL may be due to the fact that only 5 cases
examined (26%) are of GCB cell origin by immunohisto-
chemistry. Instead, we have identified the gene cyclin D
kinase inhibitor 3 (CDKN3), a known marker of the
ABC-like DLBCL [29], to be expressed higher in our
DLBCL samples compared to the other diagnostic types
examined in this study.
The lower expression of several immunoglobulin
genes in reactive node tissue may reflect the differences
in the cellular makeup of the microenvironment of
normal lymph node tissue compared to those diseased
with lymphoma. Consistent with the phenotype of non-
cancerous tissue, we detected reduced expressions of a
potentially cancerous gene TAF3, a negative regulator of
the tumour suppressor p53 [30].
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This proof of principle study has shown that microarray
as a single platform assay can achieve reasonable diag-
nostic accuracy with the ability to differentiate lym-
phoma from non-cancerous reactive lymphadenopathy,
and also classify three common subtypes of lymphoma.
Molecular classifiers identified to be characteristic of
each subtype examined could be combined onto a cost
effective custom ‘mini’ microarray to screen lymph node
biopsies for expression profiles to assist the diagnosis of
four common outcomes: reactive, cHL, FL or DLBCL in
a relatively quick and inexpensive manner. Indeed the
use of GEP as a diagnostic and prediction tool for other
diseases is currently commercially available. One exam-
ple includes the CupPrint and MammaPrint array ser-
vice provided by Agendia for patients with breast
cancer. The increased sensitivity in RNA extraction
techniques has made GEP much more widely available
even for paraffin sections, small fine needle aspiration
and core biopsies, which are routinely used in a pathol-
ogy lab. The application of GEP may streamline current
diagnostic tests by allowing more selective use of costly
and time consuming ancillary tests such as immunohis-
tochemistry, immunophenotyping by flow cytometry,
cytogenetics, FISH and PCR in every case of lymphoma.
Its use may provide an objective diagnostic test that
could be standardised across pathology laboratories.
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